title: Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
abstract: BACKGROUND
  Daclizumab high-yield process (DAC HYP), a humanized immunoglobulin G1 monoclonal antibody specific for the α subunit (CD25) of the high-affinity interleukin-2 receptor, has demonstrated efficacy for treatment of relapsing forms of multiple sclerosis in Phase II and III clinical trials.
  
  
  OBJECTIVE
  To characterize the pharmacokinetics (PK) of DAC HYP following repeated administration of the 150 mg subcutaneous (SC) dose every 4 weeks (q4wk), the proposed clinical regimen in patients with relapsing-remitting multiple sclerosis (RRMS).
  
  
  METHODS
  Twenty-six patients with RRMS received DAC HYP 150 mg SC q4wk for a total of six doses. Serial PK blood samples were collected over the first and last dosing intervals and trough PK samples were collected between these doses. Blood samples for immunogenicity assessment were collected throughout the study. Serum DAC HYP levels and anti-DAC HYP antibodies were characterized using validated immunoassays. PK parameters were estimated using noncompartmental analysis.
  
  
  RESULTS
  DAC HYP showed slow SC absorption with a median time to reach maximum observed concentration (Cmax) value of ~1 week. Steady state was reached by the fourth injection. At steady state, DAC HYP mean serum Cmax, minimum observed concentration (Cmin), and area under the concentration-time curve within a dosing interval (AUCtau) values were 29.1 µg/mL, 14.9 µg/mL, and 638 µg · day/mL, respectively, with intersubject variability of 35%-40%. The AUC accumulation ratio was ~2.5 at steady state. DAC HYP had a long elimination half-life of ~22 days and low apparent clearance (0.274 L/day). Nine patients tested positive for anti-DAC HYP antibodies, with no impact on DAC HYP clearance in this limited data set.
  
  
  CONCLUSIONS
  The PK of DAC HYP in patients with RRMS are consistent with those previously reported in healthy volunteers. The half-life of ~3 weeks and the low fluctuations in peak and trough concentrations of serum DAC HYP support the once-monthly SC dosing regimen.
authors.affiliation: Clinical Pharmacology, Biogen, Cambridge, MA, USA.
authors.forename: Jonathan Q
authors.initials: JQ
authors.lastname: Tran
authors.affiliation: Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA; Faculty of Pharmacy, Cairo University, Cairo, Egypt.
authors.forename: Ahmed A
authors.initials: AA
authors.lastname: Othman
authors.affiliation: Global Biomarker Discovery and Development, Cambridge, MA, USA.
authors.forename: Alvydas
authors.initials: A
authors.lastname: Mikulskis
authors.affiliation: Global Clinical Operation, Biogen, Maidenhead, Berkshire, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Wolstencroft
authors.affiliation: Global Clinical Development, Biogen, Cambridge, MA, USA.
authors.forename: Jacob
authors.initials: J
authors.lastname: Elkins
keywords: daclizumab high-yield process; multiple sclerosis; pharmacokinetics